Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

Zydus Lifesciences Ltd / Equity Bottom-Up

<p>Nonalcoholic fatty liver disease (NAFLD), a disorder characterized by fatty changes (and fibrosis in later stages) is expected to affect about 20 to 30% of the world's population. The disorder has been found to be linked to metabolic syndrome, which is characterized by diabetes, obesity and dyslipidemia. Non-alcoholic steatohepatitis (NASH) belongs to a more advanced stage of the spectrum of disorders under NAFLD. NASH is believed to be the second largest cause of liver transplants in the U.S…</p>

Nonalcoholic fatty liver disease (NAFLD), a disorder characterized by fatty changes (and fibrosis in later stages) is expected to affect about 20 to 30% of the world's population. The disorder has been found to be linked to metabolic syndrome, which is characterized by diabetes, obesity and dyslipidemia. Non-alcoholic steatohepatitis (NASH) belongs to a more advanced stage of the spectrum of disorders under NAFLD. NASH is believed to be the second largest cause of liver transplants in the U.S…

Saroglitazar: Targeting Non-Alcoholic Steatohepatitis, a Potential US$35-40 Billion Market.

United States

Tobira Therapeutics Inc operates as a biopharmaceutical company. The Company focuses on developing and commercializing innovative therapeutics to treat liver diseases, human immunodeficiency virus, and fibrosis and inflammation. Tobira Therapeutics conducts business in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tobira Therapeutics (TBRA US)

Saroglitazar: Targeting Non-Alcoholic Steatohepatitis, a Potential US$35-40 Billion Market.

Nonalcoholic fatty liver disease (NAFLD), a disorder characterized by fatty changes (and fibrosis in later stages) is expected to affect about 20...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)